Selim Corbacioglu is Professor and Chair of the Department of Hematology, Oncology and Stem Cell Transplantation at the Children’s Hospital in Regensburg, Germany. Professor Corbacioglu’s research interest is focused on curative options for hemoglobinopathies and transplant-related systemic endothelial complications such as VOD/SOS and PRES. As the PI of several multicentre interventional trials in children, he is the PI for a prospective international trial to evaluate haploidentical HSCT in sickle cell disease as well as one of the lead investigators of the Crisp/Cas9 based gene editing trial in sickle cell disease and thalassemia. The recipient of the Van Bekkum Award of the EBMT in 2010, Professor Corbacioglu is author of numerous peer-reviewed articles published in the New England Journal of Medicine, Lancet, Blood, Leukaemia and Bone Marrow Transplantation among others. He served as the scientific council chair of the EBMT and is currently the Chair of the Pediatric Disease Working Party of the EBMT.
